The Effect of High Polyphenol Extra Virgin Olive Oil on Blood Pressure and Arterial Stiffness in Healthy Australian Adults: A Randomized, Controlled, Cross-Over Study.
Katerina SarapisColleen J ThomasJohanna HoskinElena S GeorgeWolfgang MarxHannah L MayrGreg KennedyAndrew PipingasJane C WillcoxLuke A PrendergastCatherine ItsiopoulosGeorge MoschonisPublished in: Nutrients (2020)
Extra virgin olive oil (EVOO) is suggested to be cardioprotective, partly due to its high phenolic content. We investigated the effect of extra virgin high polyphenol olive oil (HPOO) versus low polyphenol olive oil (LPOO) on blood pressure (BP) and arterial stiffness in healthy Australian adults. In a double-blind, randomized, controlled cross-over trial, 50 participants (age 38.5 ± 13.9 years, 66% female) were randomized to consume 60 mL/day of either HPOO (360 mg/kg polyphenols) or LPOO (86 mg/kg polyphenols) for three weeks. Following a two-week washout period, participants crossed over to consume the alternate oil. Anthropometric data, peripheral BP, central BP and arterial stiffness were measured at baseline and follow up. No significant differences were observed in the changes from baseline to follow up between the two treatments. However, a significant decrease in peripheral and central systolic BP (SBP) by 2.5 mmHg (95% CI: -4.7 to -0.3) and 2.7 mmHg (95% CI: -4.7 to -0.6), respectively, was observed after HPOO consumption. Neither olive oil changed diastolic BP (DBP) or measures of arterial stiffness. The reductions in SBP after HPOO consumption provide evidence for a potentially widely accessible dietary intervention to prevent cardiovascular disease in a multiethnic population. Longer intervention studies and/or higher doses of EVOO polyphenols are warranted to elucidate the potential effect on DBP and arterial stiffness.
Keyphrases
- blood pressure
- hypertensive patients
- cardiovascular disease
- fatty acid
- heart rate
- phase iii
- randomized controlled trial
- open label
- double blind
- phase ii
- body composition
- clinical trial
- heart failure
- coronary artery disease
- cardiovascular events
- risk assessment
- big data
- skeletal muscle
- artificial intelligence
- mass spectrometry
- preterm birth
- electronic health record